Membranous nephropathy

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…

This phase 2 trial tests whether dapagliflozin, a drug used for diabetes and heart failure, can reduce harmful antibodies and prevent relapses in people with membranous nephropathy, an autoimmune kidney disease. The study enrolls 20 adults who have had a recent rise in anti-PLA2R…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

Membranous nephropathy is a rare autoimmune kidney disease where antibodies attack the kidney and can cause nephrotic syndrome. Rituximab is a routine treatment that depletes B cells, but researchers suspect it also boosts regulatory T cells, which help control immune reactions. …

This study is testing whether a prediction model can accurately forecast how quickly kidney function declines in people with primary membranous nephropathy, a kidney disease that can lead to nephrotic syndrome and kidney failure. Researchers will follow 128 adults with biopsy-con…

This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is …